Press Release
Pheonix Research Releases 2026–2033 Histopathology Forecast: Digital Pathology Grows 1.59 Times Faster and Still Takes Only Four Points of Share
FOR IMMEDIATE RELEASE
18 November 2026 — Pheonix Research has published its 2026–2033 forecast for the global histopathology market, modelling USD 17.80 billion in 2025 rising to USD 31.95 billion in 2033: a compound annual growth rate of 7.60 per cent and 1.79 times the base year.
The digitisation of the slide is the part of that market everyone assumes is about to change the market’s shape. On Pheonix’s numbers it does not. Digital pathology is modelled at USD 1.90 billion in 2025 rising to USD 4.72 billion in 2033 at 12.06 per cent — 1.59 times the rate of the total. Applied to those bases, digital pathology’s share of histopathology value moves from 10.67 per cent to 14.77 per cent: 4.10 points of share in eight years, on a technology growing nearly twice as fast as its parent market.
“The scanner is not the constraint, which is why the share line moves so slowly even at a 12 per cent rate,” said Pheonix Research’s healthcare and medical devices research team. “A glass slide that becomes a file changes the cost of storing and moving a specimen. It does not by itself change what a pathologist is paid to decide, and until the workflow around the diagnosis is repriced the digital layer can grow at twice the market rate and still be a minority of it in 2033.”
Key findings
- Histopathology: USD 17.80 billion in 2025 to USD 31.95 billion in 2033 — 7.60 per cent CAGR, 1.79 times the base year.
- Digital pathology, the digitised layer inside it: USD 1.90 billion to USD 4.72 billion — 12.06 per cent CAGR.
- Growth multiple: digital pathology compounds at 1.59 times histopathology.
- Share of histopathology value: 10.67 per cent to 14.77 per cent — 4.10 points across eight years.
- Nine tier-one players are profiled, including Roche Diagnostics and Danaher. The demand drivers the report identifies are the cancer burden, tissue-based diagnosis, laboratory automation and companion diagnostics.
- This edition publishes no unit series and no slide or case volumes. It is a value model.
“Read the two numbers together and the strategic question sharpens,” the team added. “A vendor selling into the digital layer is selling a category growing at 12 per cent into a market growing at 7.6 — genuinely faster, and still a fifth of the market by 2033. That is a good business and it is not a land grab, and the difference matters to anyone underwriting capacity, a scanner fleet or a multiple on that growth.”
The assumption that carries the forecast
The comparison rests on two Pheonix value models built on the same 2025 base and the same 2033 horizon; the share line is one divided by the other. If histopathology compounded at 6.0 per cent rather than 7.60 per cent, 2033 would be USD 28.37 billion instead of USD 31.95 billion. The claim the forecast actually makes is about mix inside pathology, not about test volumes — and the mix moves slowly.
Report details
- Title: Global Histopathology Market Report, Size & Forecast 2026-2033
- Base year: 2025 · Forecast horizon: to 2033
- Coverage: global
- Chapters: Table of Contents, Competitive Landscape, Value Chain, Investment Activity, Technology & Innovation, Market Risk, Regulatory Landscape
- Availability: Global Histopathology Market Report 2026-2033
About Pheonix Research
Pheonix Research publishes market intelligence on a live graph of more than 500 market, segment, industry, company and press-release nodes, translating market signals into role-specific decisions for procurement, strategy and executive teams. Each market report is modelled on stated assumptions and publishes the assumption that carries its forecast.
Media contact
Media and research enquiries: [email protected]
Commercial and licensing: [email protected]
— Ends —
